As shown in Figure 5, four of the tumours harbouring either KRAS or BRAF mutations showed a marked reduction (<50% of DMSO control) in the cell number in the CI-1040-treated group as compared with the other 14 tumours containing wild-type KRAS and BRAF (P<0.001). This evidence concerns the gene BRAF and neoplasm.